The neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) modulate several biochemical pathways in human leukemic myeloid cells.

Hayez N, Harfi I, Lema-Kisoka R, Svoboda M, Corazza F, Sariban E

Journal of neuroimmunology1 Apr 2004Cited by 19 (Europe PMC)

PMID15020077DOI10.1016/j.jneuroim.2003.12.008PepBankPUB-15020077

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

8 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueMechanism
In blasts isolated from patients with myeloid leukemia, VIP and PACAP both increased intracytoplasmic calcium levels.
In plain wordsIn lab tests on isolated leukemia blast cells, VIP and PACAP both raised calcium inside the cells.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseIntracytoplasmic calcium in blasts from patients with myeloid leukemia
Study
humann: not reported in source
Blasts isolated from patients with myeloid leukemia
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
Dose not stated
Source sentences
Summary
Both peptides were found to increase intra-cytoplasmic calcium levels in blasts isolated from patients with myeloid leukemia.
Report a problemFND-1502007709
02LabIn vitro (cells)Mechanism
In three of five human myeloid leukemic cell lines tested, VIP and PACAP increased cAMP levels.
In plain wordsIn lab tests on human leukemia cell lines, VIP and PACAP raised cAMP levels in three of five lines.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreasecAMP levels in myeloid leukemic cell lines
Study
humann: not reported in source
Human myeloid leukemic cell lines
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
Dose not stated
Source sentences
Summary
The neuropeptides Vasoactive-intestinal peptide (VIP) and Pituitary adenylate-cyclase activating protein (PACAP) increased cAMP levels in three out of five human myeloid leukemic cell lines tested
Report a problemFND-1502007701
03LabIn vitro (cells)Mechanism
Among five human myeloid leukemic cell lines, VIP and PACAP increased intracytoplasmic calcium levels only in the HEL cell line.
In plain wordsIn lab tests on human leukemia cell lines, VIP and PACAP raised calcium inside the cells in only one line, HEL.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseIntracytoplasmic calcium in myeloid leukemic cell lines
Study
humann: not reported in source
Human myeloid leukemic cell lines
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
Dose not stated
Source sentences
Summary
while an increased in calcium intracytoplasmic levels was seen only in one cell line (HEL).
Report a problemFND-1502007702
04LabIn vitro (cells)Mechanism
In HEL cells, the VIP and PACAP-induced increase was associated with higher c-fos protein expression.
In plain wordsIn lab tests on HEL leukemia cells, VIP and PACAP were linked to more c-fos protein.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Increasec-fos protein expression
Study
humann: not reported in source
Human myeloid leukemic cell lines
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
Dose not stated
Source sentences
Summary
This increase was phospholipase C, Pertussis toxin dependent and associated with an increase in c-fos and c-jun protein expression together with the formation of functional AP-1 transcriptional factor complex.
Report a problemFND-1502007704
05LabIn vitro (cells)Mechanism
In HEL cells, the VIP and PACAP-induced increase was associated with higher c-jun protein expression.
In plain wordsIn lab tests on HEL leukemia cells, VIP and PACAP were linked to more c-jun protein.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Increasec-jun protein expression
Study
humann: not reported in source
Human myeloid leukemic cell lines
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
Dose not stated
Source sentences
Summary
This increase was phospholipase C, Pertussis toxin dependent and associated with an increase in c-fos and c-jun protein expression together with the formation of functional AP-1 transcriptional factor complex.
Report a problemFND-1502007705
06LabIn vitro (cells)Mechanism
In HEL cells, the VIP and PACAP-induced increase was associated with the formation of a functional AP-1 transcriptional factor complex.
In plain wordsIn lab tests on HEL leukemia cells, VIP and PACAP were linked to formation of the AP-1 factor complex.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseFormation of functional AP-1 transcription factor complex
Study
humann: not reported in source
Human myeloid leukemic cell lines
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
Dose not stated
Source sentences
Summary
This increase was phospholipase C, Pertussis toxin dependent and associated with an increase in c-fos and c-jun protein expression together with the formation of functional AP-1 transcriptional factor complex.
Report a problemFND-1502007706
07LabIn vitro (cells)Efficacy outcome
Exposure of HEL cells to VIP or PACAP decreased cell proliferation.
In plain wordsIn lab tests, VIP or PACAP slowed the growth of HEL leukemia cells.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseHEL cell proliferation
Study
humann: not reported in source
Human myeloid leukemic cell lines
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Source sentences
Summary
Cell exposure to VIP or PACAP resulted in a decrease in HEL cell proliferation
Report a problemFND-1502007707
08LabIn vitro (cells)Mechanism
Exposure of HEL cells to VIP or PACAP was associated with down-regulation of the erythroid marker Glycophorin A.
In plain wordsIn lab tests, VIP or PACAP were linked to lower levels of the erythroid marker Glycophorin A in HEL cells.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseGlycophorin A expression in HEL cells
Study
humann: not reported in source
Human myeloid leukemic cell lines
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
Dose not stated
Source sentences
Summary
associated with a down-regulation of the erythroid marker, Glycophorin A.
Report a problemFND-1502007708

Studies that did not test the peptide alone1

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

09LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism
In HEL cells, the increase induced by VIP and PACAP was dependent on phospholipase C and pertussis toxin.
In plain wordsIn lab tests on HEL leukemia cells, the effect of VIP and PACAP depended on phospholipase C and pertussis toxin.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableDependence of the increase on phospholipase C and pertussis toxin
Study
humann: not reported in source
Human myeloid leukemic cell lines
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
This increase was phospholipase C, Pertussis toxin dependent and associated with an increase in c-fos and c-jun protein expression together with the formation of functional AP-1 transcriptional factor complex.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1502007703

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.